Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.

Against the trial’s posted results

• Same as the trial’s posted resultThis paper difference −8.50 (−10.2 to −6.80)Posted, primary outcome difference −8.47 (−10.2 to −6.76), p <0.0001Change From Baseline in Body Weight (Percentage [%])
• Same as the trial’s posted resultThis paper OR 13.1 (7.40–23.1)Posted, primary outcome OR 13.1 (7.40–23.1), p <0.0001Number of Participants Who Achieved Body Weight Reduction Greater Than or Equal (>=) to 5% (Yes/No)